Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01836094
Other study ID # NS 13-208
Secondary ID
Status Completed
Phase Early Phase 1
First received April 12, 2013
Last updated April 7, 2017
Start date August 2013
Est. completion date March 2016

Study information

Verified date April 2017
Source The University of Texas Health Science Center at San Antonio
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the study is to evaluate whether low-dose USP methylene blue (MB) will: i) improve short-term memory retention in a delayed match-to-sample task, ii) reduce reaction time in a psychomotor vigilance test, and iii) enhance responses to a visual-motor task as measured by functional magnetic resonance imaging (fMRI).

A single low-dose MB or placebo will be orally administered to self-declared healthy adults using double-blind study design. Non-invasive fMRI data will be acquired before and after MB administration in the same subjects. Each study will take 2-3 hours, inclusive of an hour break in between.


Description:

Self-declared healthy adult volunteers will be studied using a double-blind, placebo-controlled design. After informed consent and familiarity with the tasks and the MRI environment, the subject will enter an MRI scanner and perform the following 3 tasks:

Delayed match-to-sample task: The subject views an object for a few seconds. After a few (variable) seconds, the subject is presented with two patterns and the subject needs to press the left or right button based on whether the picture on the left or the right is the same as the previous picture. The correct and incorrect answers are recorded. A few of these trials will be cycled, lasting about 5-10 mins.

Psychomotor vigilance test: The subject will receive a visual cue to press a button as fast as possible. The reaction time is recorded. A false start is when the subject presses before the visual cue and that trial is not counted. The subject is instructed to avoid a false start. A few of these trials will be cycled, lasting about 5-10 mins.

Visual-motor task: The subject is instructed to tap his/her 4 fingers against the thumb every second and cycle through the 4 fingers, in synchrony with an alternating visual checkerboard patterns. A few of these trials will be cycled, lasting about 5-10 mins.

For calibration of the fMRI signal, fMRI data will also be acquired during a brief (3-5 mins) inhalation of 5% CO2 in air.

fMRI measurements will be made before intervention. The subject comes out of the scanner, orally ingests the USP MB or placebo, and waits for an hour (break). The same measurements will then be repeated.

fMRI data acquisition: The MRI pulse sequences include standard and non-invasive anatomical MRI for co-registration, blood flow and blood-oxygen-level dependent (BOLD) fMRI. fMRI will image changes in regional brain activity associated with these tasks.

In addition, one week after the fMRI study, the subject will be emailed a short questionnaire (which takes a few minutes to answer) and the responses can be returned via email.

Data analysis: Standard fMRI analysis will be analyzed using established fMRI software. Statistical parametric analysis will be performed to generate activation maps. Task-evoked changes in brain activities will be analyzed and contrasted between placebo and MB conditions in the same subjects. Paired t-test will be used for group comparison with P < 0.05 (with bonferroni correction) considered statistically significant.

Expected results: The investigators predict that, compared to placebo, MB will: i) improve short-term memory retention in a delayed match-to-sample task by memory performance and enhanced fMRI responses in the prefrontal cortex-hippocampus, ii) reduce reaction time in a psychomotor vigilance test and enhanced fMRI responses within a cortical sustained attention network and the motor systems, and iii) enhance responses in the visual and motor cortices.

Power analysis: Sample sizes were calculated for a power of 80%, alpha = 0.05 to detect statistical difference between MB and placebo. The investigators estimate they will need 40 subjects (complete studies) and thus will recruit 50 subjects to account for potential failed studies.


Recruitment information / eligibility

Status Completed
Enrollment 36
Est. completion date March 2016
Est. primary completion date March 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Age 18 - 65 years, self declared healthy individuals

- English speaker and be able to give consent

Exclusion Criteria:

- Contraindication for MRI (pacemaker, metal implants, etc.)

- Claustrophobia

- Pregnant (child-bearing age females will be tested to exclude pregnancy onsite)

- Breast-feeding

- A history of hypersensitivity or allergy to methylene blue, glucose-6-phosphate dehydrogenase deficiency (determined via questionnaire)

- Neurological, mental, or cardiovascular disorders

- Liver, kidney disorders, kidney or liver transplant, hypertension, diabetes, etc.

- Known hypersensitivity to thiazide diuretics and phenothiazines

- A history of a psychotic disorder or panic disorder, violent or suicidal behavior, psychiatric institutionalization or imprisonment

- Any other condition, which in the opinion of the investigator, would put the participant at risk and warrant exclusion from the study

- Methemoglobinemia

- On any psychiatric serotonergic antidepressant medication or drugs of abuse currently or within the last 5 weeks

- History of panic attack

- Color Blindness

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Methylene Blue (USP grade, 280mg oral)

Placebo
oral, one time

Locations

Country Name City State
United States Research Imaging Institute, The University of Texas Health Science Center at San Antonio San Antonio Texas

Sponsors (1)

Lead Sponsor Collaborator
The University of Texas Health Science Center at San Antonio

Country where clinical trial is conducted

United States, 

References & Publications (6)

Bruchey AK, Gonzalez-Lima F. Behavioral, Physiological and Biochemical Hormetic Responses to the Autoxidizable Dye Methylene Blue. Am J Pharmacol Toxicol. 2008 Jan 1;3(1):72-79. — View Citation

Gonzalez-Lima F, Bruchey AK. Extinction memory improvement by the metabolic enhancer methylene blue. Learn Mem. 2004 Sep-Oct;11(5):633-40. — View Citation

Lim J, Wu WC, Wang J, Detre JA, Dinges DF, Rao H. Imaging brain fatigue from sustained mental workload: an ASL perfusion study of the time-on-task effect. Neuroimage. 2010 Feb 15;49(4):3426-35. doi: 10.1016/j.neuroimage.2009.11.020. Epub 2009 Nov 24. — View Citation

Riha PD, Bruchey AK, Echevarria DJ, Gonzalez-Lima F. Memory facilitation by methylene blue: dose-dependent effect on behavior and brain oxygen consumption. Eur J Pharmacol. 2005 Mar 28;511(2-3):151-8. — View Citation

Wen Y, Li W, Poteet EC, Xie L, Tan C, Yan LJ, Ju X, Liu R, Qian H, Marvin MA, Goldberg MS, She H, Mao Z, Simpkins JW, Yang SH. Alternative mitochondrial electron transfer as a novel strategy for neuroprotection. J Biol Chem. 2011 May 6;286(18):16504-15. doi: 10.1074/jbc.M110.208447. Epub 2011 Mar 18. — View Citation

Wrubel KM, Riha PD, Maldonado MA, McCollum D, Gonzalez-Lima F. The brain metabolic enhancer methylene blue improves discrimination learning in rats. Pharmacol Biochem Behav. 2007 Apr;86(4):712-7. Epub 2007 Mar 6. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Improvement in reaction time assessed by fMRI measurements and PVT measurements fMRI will be assessed using standard fMRI analysis tools. Psychomotor-Vigilance-Test (PVT) measurements will be made using a computer program written in Psychology Experiment Building Language (PBL). 1 hour
Primary Improvement in memory assessed by fMRI measurements and DMS measurements fMRI will be assessed using standard fMRI analysis tools. Delayed-match-to-sample task (DMS) measurements will be made using a computer program written in Psychology Experiment Building Language (PBL). 1 hour
Secondary Enhanced fMRI responses to visual-motor task fMRI will be assessed using standard fMRI analysis tools. 1-2 hours
See also
  Status Clinical Trial Phase
Completed NCT03643406 - The Effect of Mental Fatigue on Lower Limb Functional Performance Tests and Brain Activity in a Healthy Population N/A
Not yet recruiting NCT04629482 - Brain Activity by Magnetoencephalography for Children
Completed NCT05049447 - Pharmacological Effects of Pascoflair® on Brain Activity in Patients Suffering From Test Anxiety Phase 4
Completed NCT05805254 - Neurofunctional Study of Preterm Infants' Brain Activity
Completed NCT02169245 - Effects of Protein and Fiber at Breakfast on Appetite, Blood Sugar, and Cholesterol N/A
Not yet recruiting NCT03192670 - A Study of Low-level Light Therapy Using Photo-activated Modulation Ameliorates Cognitive Deficits N/A
Completed NCT04030390 - The Effect of Physical Fatigue on Different Balance Tests and Brain Activity in a Healthy Population N/A
Completed NCT00728234 - Analysis of Correlation of Amplitude-Integrated EEG and Neurodevelopmental Outcome in Preterm Infants N/A
Not yet recruiting NCT02969330 - Effect of Peripheral Electrical Stimulation (PES) on Brain Response to Glucose Stimuli N/A
Completed NCT01977625 - LDX and Functional Magnetic Resonance Imaging (fMRI in Menopausal Women Phase 4
Recruiting NCT06386237 - Nutritional Modulation of Cognition and Brain Activity N/A